KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $127.7 million.

  • Xenon Pharmaceuticals' Non-Current Assets fell 2755.16% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.3 million, marking a year-over-year decrease of 2564.05%. This contributed to the annual value of $162.9 million for FY2024, which is 4907.55% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Non-Current Assets stood at $127.7 million, which was down 2755.16% from $174.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Non-Current Assets high stood at $319.8 million for Q4 2023, and its period low was $7.4 million during Q1 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Non-Current Assets had a median value of $140.3 million in 2023 and averaged $121.8 million.
  • In the last 5 years, Xenon Pharmaceuticals' Non-Current Assets surged by 147528.3% in 2022 and then plummeted by 4907.55% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Non-Current Assets (Quarter) stood at $13.0 million in 2021, then surged by 1084.63% to $153.8 million in 2022, then surged by 107.89% to $319.8 million in 2023, then plummeted by 49.08% to $162.9 million in 2024, then decreased by 21.6% to $127.7 million in 2025.
  • Its last three reported values are $127.7 million in Q3 2025, $174.0 million for Q2 2025, and $177.7 million during Q1 2025.